53 results
8-K
EX-10.1
ITCI
Intra-Cellular Therapies Inc
9 Aug 22
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:38am
. The first signs of schizophrenia typically emerge in the teenage years or early twenties. Because of the early onset and chronic nature
424B5
yx7ru
5 Jan 22
Prospectus supplement for primary offering
4:51pm
8-K
EX-99.2
ovdihtmbybqmhzn6zc
4 Jan 22
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
424B5
fin366e3 fzpm
3 Jan 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
fv67bjpm
20 Dec 21
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
7:04am
8-K
EX-99.1
s5ys500c2
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
vuwsg hcv4uykvj
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
PRE 14A
k65lu3li
19 Apr 21
Preliminary proxy
5:28pm
8-K
EX-99.1
khlq10v5aprf9
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am